Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
CNMD
CONMED Corporation
A large share of revenues comes from single-use disposable medical device products, i.e., consumables.
|
$1.21B |
$39.09
+3.11%
|
|
ABCL
AbCellera Biologics Inc.
AbCellera's primary product is its antibody discovery platform.
|
$1.20B |
$4.00
+4.57%
|
|
IRMD
IRadimed Corporation
IRADIMED monetizes proprietary disposables and consumables for its infusion pumps and monitoring devices, generating recurring revenue.
|
$1.19B |
$93.47
+1.73%
|
|
PHAR
Pharming Group N.V.
Core rare-disease therapeutic developer focused on RUCONEST and an expanding rare-disease pipeline.
|
$1.18B |
$17.54
+1.21%
|
|
MLTX
MoonLake Immunotherapeutics
MoonLake focuses on immunology therapeutics with Sonelokimab (SLK) for inflammatory skin and joint diseases.
|
$1.18B |
$18.32
+2.98%
|
|
ZBIO
Zenas BioPharma, Inc.
Company focuses on immunology-based therapeutics for autoimmune diseases.
|
$1.17B |
$21.82
+0.25%
|
|
SEPN
Septerna, Inc.
Septerna is focused on discovering and developing oral small molecule therapeutics targeting GPCRs (e.g., preclinical metabolic programs and GPCR targets under Novo Nordisk collaboration), which maps to the 'Oral Small Molecule Therapeutics' investable theme.
|
$1.17B |
$26.07
+4.32%
|
|
USPH
U.S. Physical Therapy, Inc.
Directly operates outpatient physical therapy clinics and ambulatory care services.
|
$1.16B |
$76.65
-1.96%
|
|
BHVN
Biohaven Ltd.
BHVN's Kv7 ion channel modulation platform (BHV-7000) and TRPM3 antagonist (BHV-2100) position the company in Ion Channel Modulators, a key neuroscience/pain modality.
|
$1.16B |
$10.97
+9.59%
|
|
OLMA
Olema Pharmaceuticals, Inc.
Palazestrant and OP-3136 are oral small-molecule therapeutics developed for cancer, fitting the 'Oral Small Molecule Therapeutics' category.
|
$1.15B |
$16.80
+1.91%
|
|
AZTA
Azenta, Inc.
Azenta's automated sample storage and cryogenic systems fall under Medical Devices & Biometrics.
|
$1.15B |
$25.04
+2.96%
|
|
AVNS
Avanos Medical, Inc.
The RFA portfolio (ESENTEC, TRIDENT, COOLIEF) places Avanos in the neuromodulation devices category.
|
$1.14B |
$24.63
-0.12%
|
|
GHRS
GH Research PLC
GH Research's focus on neuropsychiatric drug development (CNS/psychiatric disorders) via 5-MeO-DMT therapies.
|
$1.14B |
$18.32
+3.27%
|
|
CLOV
Clover Health Investments, Corp.
Clover Health operates Medicare Advantage plans and provides health insurance benefits.
|
$1.13B |
$2.19
+1.62%
|
|
INNV
InnovAge Holding Corp.
InnovAge provides integrated care delivery and healthcare services at PACE centers and in-home settings, the core value proposition of their business.
|
$1.12B |
$8.23
-1.61%
|
|
SPRY
ARS Pharmaceuticals, Inc.
Neffy uses a proprietary Drug Delivery Platform enabling intranasal delivery of epinephrine.
|
$1.10B |
$11.36
+1.88%
|
|
CDNA
CareDx, Inc
Directly provides Laboratory Testing & Advisory Services through its testing portfolio and diagnostic operations.
|
$1.10B |
$21.40
-4.55%
|
|
QURE
uniQure N.V.
Core business is development and commercialization of gene therapies (e.g., AMT-130) using viral vectors, i.e., direct gene therapy products.
|
$1.10B |
$17.59
+4.64%
|
|
COLL
Collegium Pharmaceutical, Inc.
Jornay PM, Belbuca, Xtampza ER, and Nucynta are all oral small-molecule therapeutics, representing major product categories in Collegium's portfolio.
|
$1.09B |
$34.42
+4.18%
|
|
NEO
NeoGenomics, Inc.
They provide comprehensive laboratory testing services and advisory support for oncology diagnostics.
|
$1.08B |
$8.37
+2.57%
|
|
GERN
Geron Corporation
Geron directly develops and commercializes RYTELO (imetelstat), an oncology therapeutic indicated for lower-risk MDS.
|
$1.07B |
$1.69
|
|
CMPX
Compass Therapeutics, Inc.
Compass Therapeutics is an oncology-focused biotech developing cancer therapies, anchoring its business in oncology.
|
$1.07B |
$5.99
-8.27%
|
|
PCRX
Pacira BioSciences, Inc.
Pacira's pMVL-based Drug Delivery Platforms enable extended-release formulations used in EXPAREL and ZILRETTA.
|
$1.06B |
$24.75
+3.73%
|
|
PNTG
The Pennant Group, Inc.
Pennant's direct service offerings include Home Health and Hospice care across the post-acute continuum.
|
$1.06B |
$30.74
+1.05%
|
|
XERS
Xeris Biopharma Holdings, Inc.
Xeris's XeriSol and XeriJect drug-delivery platforms enable stable, ready-to-use injectable formulations, a core differentiator.
|
$1.06B |
$6.38
+4.17%
|
|
TWFG
TWFG, Inc. Common Stock
Distributes health insurance products.
|
$1.06B |
$18.69
-0.95%
|
|
URGN
UroGen Pharma Ltd.
ZUSDURI (UGN-102) is an oncology therapeutic developed by UroGen, placing the company in Biotech - Oncology.
|
$1.06B |
$22.58
+5.56%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Amphastar is advancing biosimilar programs (AMP-004) and positions biosimilars as a core growth pillar.
|
$1.05B |
$22.84
+4.72%
|
Showing page 14 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
